The most powerful MRI in the world studies the effects of COVID and myalgic encephalomyelitis / brain fatigue.

Published Date: 15 Mar 2023

For the first time in the world, researchers at Griffith University have used ultra-high magnetic field (7 Tesla) MRI to examine how COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS ) affect the same brain.

Read Full News

Latest News

Tylenol Use in Pregnancy May Be Linked With Uterus, Ovary Changes in Daughters

Female reproductive organ development may be impacted by a mother's use during pregnancy of Tylenol or its generic versions, according to researchers who emphasize that...

Ionis Pharma Prices First FDA-approved Treatment for Alexander Disease At $285,000 Per Dose

Ionis Pharmaceuticals said on Friday it would price its newly approved therapy ⁠to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the...

New Migraine Prevention Guidelines Released

Updated migraine prevention guidelines recommend preventive treatment for patients with ≥ 4 migraine days per month and incorporate CGRP-targeted therapies into individualized treatment selection.

Novartis Pauses Trials Of Experimental Cell Therapy After Three Deaths

Novartis said on Tuesday it paused eight clinical trials of an experimental cell therapy, called rap-cel, targeting autoimmune and neurological disorders in late ⁠August,...

New Stroke Rehab Guideline Calls for Earlier, Broader Care

The first update to adult stroke rehabilitation and recovery guidelines in a decade emphasizes early, individualized care addressing physical, cognitive, communication, and mental health needs.

Borderline Personality: Evidence Has Evolved. Care Hasn’t

A quiet revolution in borderline personality disorder has exposed a disconnect: Treatment works, recovery is possible, yet outdated assumptions continue to shape clinical care.

Todays Updates

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

Todays Updates

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

Latest News

Female reproductive organ development may be impacted by a mother's use during pregnancy of Tylenol or its generic versions, according to researchers who emphasize that...

Ionis Pharmaceuticals said on Friday it would price its newly approved therapy ⁠to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the...

Updated migraine prevention guidelines recommend preventive treatment for patients with ≥ 4 migraine days per month and incorporate CGRP-targeted therapies into individualized treatment selection.

Novartis said on Tuesday it paused eight clinical trials of an experimental cell therapy, called rap-cel, targeting autoimmune and neurological disorders in late ⁠August,...

The first update to adult stroke rehabilitation and recovery guidelines in a decade emphasizes early, individualized care addressing physical, cognitive, communication, and mental health needs.

A quiet revolution in borderline personality disorder has exposed a disconnect: Treatment works, recovery is possible, yet outdated assumptions continue to shape clinical care.

News All Time

Dravet Syndrome Clinical Pearls: Uncovering Disease Impact and Partnering With Patients and Caregivers to Individualize Treatment Plans

Dravet Syndrome Clinical Pearls: Uncovering Disease Impact and Partnering With Patients and Caregivers to Individualize Treatment Plans

Leptomeningeal Metastases: Early Recognition, Diagnosis, and Multidisciplinary Care

Leptomeningeal Metastases: Early Recognition, Diagnosis, and Multidisciplinary Care

Decoding Leptomeningeal Metastases: Strategies for Early Detection and Accurate Diagnosis

Decoding Leptomeningeal Metastases: Strategies for Early Detection and Accurate Diagnosis

Superagers' Exceptional Memory Can't Be Explained by Genes Alone, Study Finds

Inherited Alzheimer's risk didn't differ between superagers and cognitively average older adults

Diarrhea Bug Outbreak Hits 4 More States; Fauci to Testify; Doc Dies in House Fire

Health news and commentary gathered by MedPage Today staff

Hold Off on JAK Inhibitors in Rheumatoid Arthritis Until After Shingles Vax?

Good things come to those who wait -- and to those who don't wait

FDA Approves Tylenol With Naproxen Combination

First OTC fixed-dose combination product to pair acetaminophen with naproxen sodium

FDA Panel Finds a Peptide It Doesn't Like

Over 2-day meeting, six of seven peptides are recommended for adding to bulk compounding list

Brain Worm Culprit in Woman's Hallucinations, Incoherent Speech

MRI uncovers neurocysticercosis in a 52-year-old woman

First-in-Class Drug for ADHD Wins FDA Approval

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older

FDA Scientists Raise Questions About Duchenne Drug

Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data

Feds Delay Autism Meeting; Wildfire Smoke and Migraine; Mortality and MS

News and commentary from the world of neurology and neuroscience

Sugar Rationing in Early Life Linked to Lower Dementia Risk Decades Later

Long-term study looks at what happened when sugar was scarce

FDA Committee Votes Down Duchenne Drug

Agency staff and drug developer disagree on endpoints

Alzheimer's Paper Retracted; MS Before Epstein-Barr Infection; Brain Aging Map

News and commentary from the world of neurology and neuroscience

Fauci Successor Imminent; CDC Expands Outbreak List; Pesticides Linked to ALS

Health news and commentary gathered by MedPage Today staff

Recommended News For You

Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

In prostate cancer survivorship, sleep disturbances are underappreciated.

In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.

For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.

The FDA Approves the New Frontline Aggressive ALL Regimen.

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

Recommended Articles For You

Clinical Pharmacology of Iron Homeostasis Regulatory Therapeutics 

Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial 

Hematopoietic Aging and Long-Term Disease Risk: Mechanisms, Clinical Impact, and Emerging Therapeutic Strategies 

Gene-Regulated Hematopoietic Restoration Technologies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early Tislelizumab May Boost PFS in Esophageal Cancer

2.

BMTs that are "half-matched" are effective in treating severe sickle cell disease.

3.

Despite reports of hundreds of cancer cases, carcinogens have been discovered at nuclear missile sites in Montana.

4.

Obesity-associated cancers may be on the rise in Puerto Rico

5.

Chris Hoy reveals that he has terminal cancer?here's how to spot early signs of prostate cancer

1.

Hematopoietic Lineage Commitment Through Single-Cell Functional Genomics: Insights, Mechanisms, and Clinical Implications

2.

Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology

3.

Gender-Specific Dual Antiplatelet Therapy Strategies for Women After PCI

4.

Integrative Clinical Genomics of Metastatic Cancer: Decoding Tumor Evolution for Precision Oncology

5.

Senescence in Cancer Therapy: Mechanisms, Clinical Relevance, and Therapeutic Implications

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV

2.

Chemotherapy: What to Expect

3.

Understanding the Common Causes of Anemia

4.

Understanding the Role of Multidisciplinary Cancer Care

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot